Yes I know Im on holiday so Ill make it quick. Just had a phone call and an e- mail from a City pal of mine and hes drooling over this company. Hes a trust worthy chap and has given me some fantastic tips over the last 10 years.
Hes going on about it being a ten bagger, but I dont like that kind of talk, best to just see how the market rates it. He says theres going to be a lot of news flow so that should provide for a momentum driven price. Have to say I have never known him quite so excited about a stock. Ive just gone in and bought a nice holding.

Heres the e-mail he sent me. It might be worth your while having a dabble. Citywire seem to think its going to be a hit.

Health minnow makes strong return to market
Published: 11:51 Wed 22 Oct 2003
By Joanne Wallen, Associate Editor
Email to a friend


The chief of Healthcare Enterprise Group sold his last business to private healthcare firm Bupa and he's now raring to go again; the business may be worth a second look.

Shares in the 24 million AIM-listed business were suspended in August pending a couple of key acquisitions, and returned to the market on Monday after the deals were announced.


Healthcare Enterprise Group (HCEG) (HCEG) paid a total of 11.5 million for the Safa Group and Industrial Pharmaceutical Service (IPS) as well as a 60.7% stake in SafaTec. The company raised a total of 10 million via a placing of shares at 1p to fund the acquisitions and also took on 3.5 million of bank debt.


Chairman Stuart Bruck, who previously founded private medical services business Barbican, which he sold to Bupa in January 1999, is hoping to build a significant business providing medical services to corporate customers. He is hoping to be a consolidator in what he told Citywire is a very fragmented market.


Both Safa and IPS provide first aid kits, training, first aid suites and a host of other medical and occupational health services to large corporate customers such as British Airways, Marks & Spencer, BT, Sainsbury and government procurement agency OGC. Both companies also have advanced 'replenishment systems,' which enable companies to maintain adequate supplies to satisfy UK health and safety legislation.


Bruck said these acquisitions would provide a 'platform' for further acquisitions.


The company had previously accrued minority stakes in a total of 14 small healthcare services companies in the UK and the US. In March it listed on AIM by reversing into a cash shell.


Bruck said the minority stakes offered it an entry into the market, but the company has now decided to focus on wholly operating and owning businesses. It has therefore identified four of its US businesses that it would like to buy the remaining stakes in. These are all within a two hour drive of the company's Los Angeles office, and would be run from there.


The company has also 'packaged up' the remaining eight businesses with a view to selling each of its minority stakes. Bruck said the pricing being talked about is already ahead of the indicative pricing given in March.


Safa and IPS apparently already have a 30% share of the corporate medical services market in the UK. They are both cash generative from operating activities. Both companies are based in the North of England and do not have a huge penetration in London, where Bruck believes the company has 'a huge opportunity.'


He reckons they have so far penetrated around 50% of the FTSE 100, and therefore have a 'great client base' to which they should be able to sell additional services.

SafaTec has interests in a number of early stage companies that have developed some innovative healthcare products and technologies, which the company is hoping to commercialise. For example, Safa has secured a sole international distribution agreement with Ebiox, a manufacturer of a unique decontaminant and cleansing product range based on a patented formula. SafaTec UK has a 35% interest in Ebiox and HCEG is negotiating to acquire a controlling interest for the enlarged Group.


Bruck does not expect to make any more major acquisitions in the next year or so, but thinks there are a lot of small players that the company might be able to mop up.


'This is very exciting, I am looking forward to digging in,' he said.


Shares are currently at 1.7p.


Citywire Verdict:


The corporate healthcare market is becoming increasingly regulated, which favours HCEG. Bruck's track record should also be worth buying into.


The corporate structure looks pretty complicated at present with all of the minority shareholdings, but Bruck now seems keen to get the point quickly where HCEG controls the majority of the businesses it operates.


This is obviously early days, but for anyone that fancies a speculative punt on a penny share, HCEG is worth a second look.ENDS.

Well it looks very good to me although its a speculative punt, what isnt in the markets today. Good chance to get on board aswell on a bad day.

Please DYOR. You are responsible for your own buying and selling actions.

GF.

RNS Number:2788L
Healthcare Enterprise Group PLC
20 April 2005

Healthcare Enterprise Group

Announcement of Notifiable Interest of Shares


Healthcare Enterprise Group PLC ("HCEG") was notified on 19 April 2005 that FMR
Corp and its direct and indirect subsidiaries, and Fidelity International
Limited (FIL) and its direct and indirect subsidiaries, both being
non-beneficial holders, have an interest of 6,012,334 ordinary shares in HCEG,
being approximately 4.0% of the issued share capital of the HCEG of 150,354,079
ordinary shares.



20 April 2005


This information is provided by RNS
The company news service from the London Stock Exchange
END

This is good news. LOL

Healthcare Enterprise answer to superbugs
24 April 2005

THE MRSA hospital superbug has become a hot General Election issue. Actress Leslie Ash, who nearly died after contracting a similar virus, has taken up the cause by leading a campaign to improve cleanliness in the NHS.

Whether she will be as successful as celebrity chef Jamie Oliver was in his crusade over school meals has yet to be seen. But with hospital bugs claiming 5,000 lives each year, this is an issue that no Government can afford to ignore.

One company well placed to benefit from this greater awareness of superbugs is Healthcare Enterprise. It has a unique cleaning agent, Ebiox, which has a wide range of applications. The germicide is effective against numerous organisms, including MRSA, but unlike other methods of hand cleaning, which involve abrasive alcohol-based agents, it has no toxicity problems. The basic patent runs until 2019.

Healthcare already supplies Ebiox as a surface wipe to about 80 UK hospitals. But given the scale of the superbug crisis, chairman Stuart Bruck is at a loss to explain why orders from the NHS for its Ebiox hand rub, whose efficacy is not in doubt, have yet to materialise.

But instead of blaming sclerotic NHS bureaucracy for the delay, Bruck is busy winning sizeable orders elsewhere. Significant contracts include one for pharmaceutical clean rooms in America, while interest in Asia is high, not least because Ebiox also acts against the bird-flu virus.

Potential orders from these and other markets, including household and dental, run into hundreds of millions of pounds and such is the confidence in the future that Healthcare recently bought out the minority stake in Ebiox.

But Healthcare is more than just a one-product firm. It has other products in development, notably Optiscope, which is a cheap, disposable endoscope for use in keyhole surgery. Patented until 2023, Optiscope is in the prototype stage and will target users of the 250m global market for conventional endoscopes, which are expensive to make and difficult to clean.

Midas verdict: Valuing a company such as Healthcare is difficult and forecasts are tentative. But based on research by the company's broker, Numis, Healthcare is expected to make a small profit this year, which could rise to 8.5m in 2006 and 28m the year after.

That would put the shares, now 99p, on a price-to-earnings multiple of 30, falling to just nine for 2007. While the risks associated with investing in a company like this cannot be understated, we believe Healthcare has an exciting product range and rate the shares a speculative buy.

• Midas is Edited by Patrick Tooher

seeing as it has been tipped and also following the Newsnight feature in which HCEG was pretty prominent and also believe there is a piece on the MW boards things are looking up could be an interesting week.

Another one to keep an eye on i think.

MeDilator :

http://v3.espacenet.com/textdoc?DB=EPODOC&IDX=AU2003224416&F=0

Yet more excellent news from HCEG


RNS Number:2065M
Healthcare Enterprise Group PLC
12 May 2005

HCEG formalises commercial presence in Japan

HCEG, the international healthcare products and services company has established a branch office in Tokyo, Japan. This office will trade to the healthcare, industrial, institutional and consumer markets.

The branch will be managed by Mr Yuta Ito. Mr Ito is a highly experienced healthcare products professional who is both well known and well respected in the Japanese healthcare market. He has over 20 years sector experience, most latterly with IMI and Heart Laboratories - both of which specialise in the field of medical devices.

Mr Ito will report directly to Group CEO, Gordon Wood.

Stuart Bruck, Executive Chairman, HCEG, commented:

"The significant interest for our products in Japan has necessitated the establishment of our own presence in this, the world's second largest economy.

"We are delighted to have secured the services of yet another high calibre individual who can assist us in both the commercial and technical processes unique to the Japanese market, and the establishment of distribution partners for our products across a number of market sectors."

Excellent. This company is going places. Now all we need is for the share price to follow.

International Market Intelligence is a company involved in the distribution of medical devices and equipment into the Critical Care Sector



Their main web site is in Japanese but there is an abbreviated English site at:



http://www.mmjp.or.jp/IMI/motto.htm







Likewise you can see an abbreviated English version of the Heart Labs site at







http://cc.msnscache.com/cache.aspx?q=1763351409229〈=en-GB&FORM=CVRE



I am personally delighted to have Yuta on board. He is a well know and respected operator in the Japanese market and has already assisted us in the fast tracking of some of our products through the regulatory maze that is the Japanese healthcare market.

I will be visiting a number of key potential distributors with Yuta at the end of this month and it is necessary that we have an on-site contact of this level taking care of these accounts on our behalf in Japan



Kind Regards

What, no interest? Mind you, the rival board is one of the best bbs available.

http://moneyam.uk-wire.com/cgi-bin/articles/200505270700218401M.html

Shares tightly held by intis -only around 12% in free float, excellent management, products and results. Broker target 155p.

LONDON (AFX) - Healthcare Enterprise Group PLC reported a sharp reduction in losses today on the back of a surge in turnover to 15 mln stg from 3 mln a year earlier.

The group also announced today that it has agreed its first distribution contract in China, with a major Chinese distributor, Chung Fai International Development Company.

The agreement covers the Beijing area of China with an initial 7 mln usd contract for the distribution of its Ebiox range of instrument decontamination products.

HCEG said it is also in discussions with other partners regarding distribution agreements for other areas in China.

Turning to results for the year, Healthcare said its pretax loss fell to 322,000 stg from a loss of 2.9 mln.

Chairman Stuart Bruck said that, having successfully consolidated the cash generative occupational healthcare and first aid business the group is now seeing its first product platform, Ebiox, win major initial contracts and distribution agreements.

'We are on track to launch Optiscope in 2006 having secured a significant partnership with JENOPTIK AG and there are further product platforms in the pipeline,' he added.

In the coming months, Bruck said trading should continue in line with expectations with significant newsflow on acquisitions, distribution agreements and on one or more new product platforms. newsdesk@afxnews.com

This is going to be a fantastic growth stock IMHO. Held these for about a year now. The only way is up.

zscrooge, yes, other BBoard is much better.

LOL

saw hceg for the first time today the results show that this one is a winner or I'm a dutchman

good news for the stock,good delivery by the board,obviously due a huge rise and also think other board better.

HCEG , always on the go :
"Unfortunately I will be on a plane to Japan this afternoon so the bank holiday is out for me!

That said, I am looking forward to what will hopefully be a very fruitful series of meetings firstly in Japan over the next five days, then down to Los Angeles at the weekend."

May our thoughts be with them .

HCEG claim that Ebiox kills Avian Flu Virus,meaning that it can be used to clean surfaces which might be infected.Why has the share price been allowed to languish?
IMO this company has many excellent products and should be supported by investors,not ignored.
Ethel

ethel I agree this is a very good company with excellent products. WE NEED NEWS to move this again.

What a rare and splendid opportunity to buy in to this stock i do not think that we will see this sp again on such a quality company

Loadsa

Buys coming in faster now, if your of a mind to get on board best do it today I think
Loadsa

Moving up nicely

Loadsa

There appears to be some conflicting reports about Bioquell (A Quoted Client of Investec) and HCEG . Bioquell with similar problems as HCEG was given a hold by Investec and HCEG was given a reduce .Gratefully researched by another member of this board .

Investec Widens Bioquell 05 Pretax Loss

Wednesday, September 28, 2005 12:07:36 PM ET
Dow Jones Newswires



1556 GMT [Dow Jones] Investec Securities expects Bioquell (BQE.LN) to make a pretax loss of GBP500,000 in 05 against previous expectations of break even. The move takes into account slower-than-expected trading in 1H but would have been worse were it not for IFRS, under which the company is forced to capitalize development expenditure, thus reducing operating costs. In 06 pegs pretax profit at GBP500,000 and in 07 at GBP1M. Maintains hold recommendation. Closed unchanged at 100.25p. (DWE)


Contact us in London. +44-20-7842-9464
Markettalk.eu@dowjones.com



(END) Dow Jones Newswires

September 28, 2005 11:56 ET (15:56 GMT)

Copyright (c) 2005 Dow Jones & Company, Inc.

Taken form:

http://www.newratings.com/analyst_news/article_1038205.html
--------------------------------------------------------------------------------